Want to see TEM full AI Analyst Report?
TEM Stock Chart & Stats
$55.87
-$0.17(-0.45%)
At close: 4:00 PM EST
$55.87
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$41.73 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)6.36M
Market Cap
$10.54B
Enterprise Value$9.31B
Total Cash (Recent Filing)$639.07M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta3.05
Next Earnings
Jul 30, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding174,520,980
10 Day Avg. Volume4,534,288
30 Day Avg. Volume6,362,405
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue6.83
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-68.67
Forecast
1Y Price Target
$65.77Price Target Upside17.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$1.59B
Bulls Say, Bears Say
Bulls Say
Proprietary Data Asset & ML PlatformA >500PB proprietary clinico-molecular dataset plus GPU model-building creates a durable competitive moat: it enables differentiated AI products, recurring data licensing, and deepening pharma partnerships. Scale and unique data improve customer stickiness and long-term monetization potential.
Strong Top-line Growth And Upgraded GuidanceSustained high-single to mid-30s revenue growth with a raised annual guide and positive adjusted EBITDA target signals scalable demand and operating leverage. This trajectory supports reinvestment into products and data while indicating a credible path toward sustained profitability if execution continues.
Data & Applications Momentum And Contract VisibilityRapid Data & Applications growth and repeated >$100M bookings quarters point to higher-margin, recurring revenue and strong enterprise demand. Growing bookings/TCV provide multi-quarter visibility and strengthen long-term relationships with pharma and health-system customers, improving revenue durability.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow forces reliance on external financing to fund growth and working capital. Over months this reduces flexibility for opportunistic investments, raises refinancing risk, and can pressure margins if the company must prioritize liquidity over strategic initiatives.
Elevated LeverageMaterial debt levels relative to equity constrain strategic flexibility while operating losses persist. Elevated leverage increases interest and refinancing sensitivity, making the company more vulnerable to cash-flow variability and potentially limiting R&D, commercial expansion, or M&A that underpin long-term growth.
MRD Reimbursement And Scaling RiskMRD offers material upside but depends on reimbursement and scalable unit economics. Regulatory and payer timing uncertainty means growth could require sustained subsidization, raising cash needs and delaying margin improvement if reimbursement lags or pricing remains constrained.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $41.73 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $10.54B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Jul 30, 2026 which is in 14 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on May 05, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.07.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.15.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 174,520,980 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -1.054%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.77 (17.72% Upside)
$65.77 (17.72% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 70%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.43%
12-Months-Change
Fundamentals
Return on Equity
-70.24%
Trailing 12-Months
Asset Growth
38.36%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Stock 12 Month Forecast
Average Price Target
$65.77
▲(17.72% Upside)
Technical Analysis
Ownership Overview
22.44% Insiders
8.88% Mutual Funds
0.03% Other Institutional Investors
52.48% Public Companies and Individual Investors